Stocktoria
Altimmune, Inc. ALT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2005-10-06
Altimmune, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $41,000 | $20,000 | $426,000 | -$68,000 | $4.4M |
| R&D expense | $66.4M | $82.2M | $65.8M | $70.5M | $74.5M |
| Operating income | -$94.5M | -$103.2M | -$95.9M | -$87.7M | -$96.9M |
| Interest expense | — | — | $35,000 | $8,000 | $5,000 |
| Income tax | -$681,000 | — | — | -$197,000 | — |
| Net income | -$88.1M | -$95.1M | -$88.4M | -$84.7M | -$97.1M |
| EPS (diluted) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| Operating cash flow | -$67.5M | -$79.8M | -$75.8M | -$62.6M | -$78.2M |
| Free cash flow | -$67.5M | — | -$75.9M | -$62.7M | -$90.4M |
| Cash & equivalents | $43.8M | $36.9M | $135.1M | $111.1M | $190.3M |
| Total assets | $279.9M | $139.3M | $210.6M | $206.9M | $218.9M |
| Total liabilities | $55.0M | $15.8M | $16.5M | $21.6M | $19.7M |
| Shareholders' equity | $224.9M | $123.5M | $194.1M | $185.3M | $199.1M |
Source: SEC EDGAR filings · CIK 0001326190 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.